¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"morphine like drug"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antiseptic drug
    1. ¹æºÎÁ¦ 2. »ì±ÕÁ¦
  • antithyroid drug
    °©»ó»ù¾à, Ç×°©»ó¼±Á¦
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
  • autonomic drug
    ÀÚÀ²½Å°æ¾à
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • adrenergic drug
    ¾Æµå·¹³¯¸°ÀÛ¿ë¾à
  • adverse drug reaction
    ¾à¹°À¯ÇعÝÀÀ
  • crude drug
    »ý¾à
  • cutaneous drug reaction
    ÇǺξ๰¹ÝÀÀ
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°
  • drug
    1. ¾à, ¾à¹° 2. ¾àÁ¦
  • drug abstinence
    ¾à¹°±Ý´Ü
  • drug abuse
    ¾à¹°³²¿ë
  • drug acne
    ¾à¹°¿©µå¸§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antiseizure drug
    °æ·Ã¾à, Ç×°æ·ÃÁ¦
  • antiseptic drug
    Ç×±Õ¾à
  • antithyroid drug
    °©»ó»ù¾à, Ç×°©»ó»ù¾àÁ¦
  • antituberculosis drug
    °áÇÙ¾à, Ç×°áÇÙÁ¦
  • antiviral drug
    ¹ÙÀÌ·¯½º¾à, Ç×¹ÙÀÌ·¯½ºÁ¦
  • arsenic drug
    ºñ¼Ò¾à
  • autonomic drug
    ÀÚÀ²½Å°æ¾à
  • awaking drug control law
    °¢¼ºÁ¦Á¶Àý¹ý
  • drug abstinence
    ¾à¹°±Ý´Ü, ±Ý´Ü
  • drug abuse
    ¾à¹°³²¿ë
  • drug acne
    ¾à¹°¿©µå¸§
  • drug addiction
    ¾à¹°Áßµ¶
  • drug adjuvant
    ÀǾàǰ÷°¡¹°
  • drug adsorption
    ¾à¹°ÈíÂø
  • drug allergy
    ¾à¹°¾Ë·¹¸£±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • antiemetic drug
    ÁøÅäÁ¦, Ç×±¸ÅäÁ¦.
  • antihistaminic drug
    Ç×È÷½ºÅ¸¹Î(¼º)¾à.
  • antihypertensive agent =a. drug
    Ç÷¾Ð°­ÇÏÁ¦, °­¾Ð¾à, Ç×°íÇ÷¾Ð(Áõ)¾à.
  • antimuscarinic drug
    Ç×¹«½ºÄ«¸°Á¦, Ç×¹«½ºÄ«¸°(¼º)¾à
  • antiobestic drug
    »ìºüÁü¾à, Ç׺ñ¸¸¾à (ù÷ÝþØ»å·).
  • antiplatelet drug
    Ç×Ç÷¼ÒÆÇ¾à.
  • antipruritic drug
    Ç×¼Ò¾ç¾à£¬Áø¾ç¾à(òååÊå·), °¡·Á¿òÁ¦Áö¾à.
  • antipsychotic drug
    Ç×Á¤½Åº´¾à(ù÷ïñãêÜ»å·).
  • antipsychotic drug
    Ç×Á¤½Åº´¾à
  • antipyretic drug
    ÇØ¿­¾à(ú°æðå·).
  • antiseborrheic drug
    Ç×Áö·ç¾à(¡­å·).
  • antiseizure drug
    Ç×°æ·Ã¾à(ù÷ÌâÕýå·).
  • antiseptic drug
    ¹æºÎ¾à(¡­¾à).
  • antispirochetal drug
    Ç×½ºÇÇ·ÎÇ쟾à.
  • antispirochetic drug
    Ç×½ºÇÇ·ÎÇ쟾à.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • morphea-like basal cell carcinoma
    ±¹¼Ò °æÇÇÁõ¾ç ±âÀú¼¼Æ÷¾Ï
  • non-suppressible insulin-like activity
    ºñ¾ïÁ¦Àν¶¸°¾ç Ȱ¼º
  • norwalk-like virus
    ³ë¸£¿öÅ© (Norwalk) ¸ð¾ç ¹ÙÀÌ·¯½º(¡­Ù¼åÆ ¡­)
  • organic schizophrenia-like disorder
    ±âÁú¼º Á¤½ÅºÐ¿­À¯»çÀå¾Ö(º´)
  • organism, pleuropneumonia-like (PPLO)
    Æó´Á¸·¿°À¯»ç º´¿øÃ¼, PPLO, ¹ÌÄÚÇö󽺸¶
  • parvovirus-like agent
    ÆÄº¸¹ÙÀÌ·¯½ºÀ¯»ç º´¿øÃ¼
  • plate like atelectasis
    ÆòÆÇ¾ç ¹«±âÆó, ÆÇ¾ç ¹«±âÆó
  • pleuropneumonia-like organism
    Æó´Á¸·¿°À¯»ç º´¿øÃ¼, PPLO, ¹ÌÄÚÇö󽺸¶
  • pleuropneumonia-like organisms(p.p.l.o)
    ¿ìÈ丷Æó·Å±Õ(éÚýØØ¯øËæúж)
  • reflex like reaction
    ¹Ý»ç¾ç¹ÝÀÀ(ÚãÞÒåÆÚãëë).
  • ribbon like keratitis
    ´ë»ó°¢¸·¿°(ÓáßÒÊÇØ¯æú)
  • rosacea like tuberculid
    ÁÖ»ç¾ç °áÇÙÁø
  • rosacea-like erutpion
    ÁÖ»ç¾ç ¹ßÁø
  • schizophrenia-like disorder, organic
    ±âÁú¼º Á¤½ÅºÐ¿­º´À¯»çÀå¾Ö(º´)
  • serum sickness-like syndrome
    Ç÷ûº´ À¯»çÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
C&M cocaine and morphine
DNPM dinitrophenol-morphine
HIMT hemagglutination inhibition morphine test
HMC hand-mirror cell; health maintenance cooperative; heroin, morphine, and cocaine; histocompatibility ...
IEMCT individualized epidural morphine conversion tool
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ADAP AIDS Drug Assistance Program
ADE Adverse Drug Event
ADR Adverse Drug Reaction
ADAMHA Alcohol, Drug Abuse, and Mental Health Administration
AED Antiepileptic drug
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • pseudopod-like outgrowth
    À§Á· °°Àº µ¹Ãâ
    °¡Â¥ ´Ù¸®°°ÀÌ Æ¢¾î³ª¿Â µ¹Ãâ¹°.
  • pyoderma granulosum-like ulcer
    ±«Àú¼º ³óÇǼº ±Ë¾ç
  • ribbon like keratitis
    ´ë»ó °¢¸·¿°
  • stalk like
    Áٱ⠰°Àº
  • tapioca like
    ŸÇÇ¿ÀÄ« °°Àº
  • tumor like focal thickening
    Á¾¾ç °°Àº º´¼Ò ºñ´ë
  • tumor like swelling
    Á¾¾ç¼º ºÎÁ¾
  • web like
    °Å¹ÌÁÙ °°Àº
  • yeast like
    È¿¸ð¾ç
  • addicting drug
    ½À°ü¼º ¾à
  • adrenergic stimulating drug
    ¾Æµå·¹³¯¸° ÈïºÐ ¾à, ¾Æµå·¹³¯¸°¼º ÈïºÐ¾à, ¾Æµå·¹³¯¸° ÀÚ±ØÁ¦, ¾Æµå·¹³¯¸°¼º ÀÚ±ØÁ¦
  • adverse drug reaction
    ¾à¹°ÀÇ ºÎÀÛ¿ë
  • anesthetic drug
    ¸¶Ãë ¾à
  • antagonistic drug
    ±æÇ× ¾à, ±æÇ×Á¦
  • antiamebic drug
    Ç׾Ƹ޹٠¾à
    ¾Æ¸Þ¹Ù¸¦ »ì¸ê ¶Ç´Â ¹ßÀ°À» ¾ïÁ¦ÇÏ´Â ¾à¹°.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
Shiga like toxin <protein> Group of structurally related toxins that block eukaryotic protein synthesis by cleaving the 28S rRNA subunit of ribosomes.
Examples: Shiga toxin, Shiga like toxins SLT 1 and SLT 2 of Escherichia coli.
(18 Nov 1997)
SLE-like syndrome <syndrome> A disease with manifestations suggestive of systemic lupus erythematosus, without meeting diagnostic criteria for that disease; sometimes used for drug-induced lupus.
(05 Mar 2000)
neoplastic endocrine-like syndromes Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm.
(12 Dec 1998)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
insulin like growth factor <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin.
They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present).
Insulin like growth factor I = somatomedin A = somatomedin C
Insulin like growth factor II = MSA (Multiplication stimulating activity).
Insulin like growth factor 1 is released from the liver in response to growth hormone.
Acronym: IGF
(18 Nov 1997)
insulin-like growth-factor binding protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29)
(12 Dec 1998)
insulin-like growth factor-binding protein 2 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth factor binding protein 3 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin like growth-factor-binding protein 4 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding-protein 5 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like-growth-factor-binding protein 6 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
insulin-like growth-factor-binding proteins A family of soluble proteins that bind insulin-like growth factors and modulate their biological actions at the cellular level. (int j gynaecol obstet 1992;39(1):3-9)
(12 Dec 1998)
insulin-like growth factor I <chemical> A well-characterised basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be mainly active in adults in contrast to insulin-like growth factor II, which is a major foetal growth factor.
Chemical name: Insulin-like growth factor I
(12 Dec 1998)
insulin-like growth factor II <chemical> A well-characterised neutral peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like and mitogenic activities. The growth factor has a major, but not absolute, dependence on somatotropin. It is believed to be a major foetal growth factor in contrast to insulin-like growth factor I, which is a major growth factor in adults.
Chemical name: Insulin-like growth factor II
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • soft drug
    ¾àÇÑ ¸¶¾à(¸¶¸®È­³ª µûÀ§)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á